LGD‑4033 – Dosage and Cycle Strategies for Optimal Results

LGD-4033 or Ligandrol is a selective androgen receptor modulator (SARM) that was clinically proven to support lean muscle mass building.[1] This makes it a popular choice for sports supplementation. But do you know about the other potential benefits of LGD-4033? Or, do you know how to dose the LGD-4033 SARM? If not, read this article – we’ll answer all your questions!

Key Takeaways

• LGD-4033 has multiple potential benefits for athletic performance, including:
  • muscle growth support,
  • boost in muscle strength,
  • enhanced post-workout recovery,
  • lean mass preservation.
• How to dose and cycle LGD-4033? Ideally, you should take one 10mg dose each morning, with a meal. However, you may alter it to two 5mg doses throughout the day.
• The cycle for LGD-4033 intake should be about 8-12 weeks long. Afterwards, take a 4-week break from the supplement.

What IS LGD-4033 in a Nutshell

LGD-4033 is a SARM – selective androgen receptor modulator. This means that it works similarly to steroids, with one exception: it targets mostly bone and muscle tissue, without affecting the rest of your body. LGD-4033 specifically is one of the most well-researched SARMs – it has been proven to have minimal side effects, while supporting lean muscle mass building and preservation.

Learn more about SARMs in our article: Complete Beginner’s Guide to SARMs

Ligandrol (LGD-4033) Benefits

Ligandrol is popular due to its potential benefits for athletic performance. It has been established to support lean muscle mass building even in small doses (1mg/day).[1] However, it may also boost:

• strength,
• recovery,
• and bone density.

Interestingly enough, these benefits were observed not only among athletes. One study in 2018 has shown LGD-4033 increasing lean muscle mass (and mobility) among the elderly (tested on people over 65) recovering from hip fractures.[2] This further proved Ligandrol’s outstanding effects.

When and How to Take LGD-4033? Dosage and Cycling

Dosage

There are two ways to take Ligandrol: once or twice daily. However, the daily LGD-4033 dosage always remains the same: 10mg. Here’s how it works in practice:

• 1x 10mg daily – take it in the morning, with your breakfast.
• 2x 5mg daily – take it in the morning with your breakfast, and in the afternoon with your lunch.

Cycling

Ligandrol cycling is individual – you always have to monitor your body and see how you react to this SARM. Nevertheless, the usual cycle spans between 8-12 weeks.

After a cycle, you should consider a mild post-cycle therapy – a recovery regimen that will help you restore your body and hormones to regular function. Moreover, you should refrain from starting another cycle for at least 4 weeks.

Stacking Other SARMs with Your LGD-4033 Dosage

Can you stack other SARMs with Ligandrol? It is possible. Some of the most common combinations include:

• stacking with muscle growth SARMs, such as MK-677,
• stacking with muscle strength SARMs, such as YK-11,
• stacking with fat-loss SARMs, such as SR9009.

Conclusion

Ligandrol is one of the most well-researched SARMs for muscle mass building. The standard LGD-4033 dosage is 10mg daily in an 8-12 week cycle. When to take it? You can either take 10mg once in the morning, or 2x5mg in the morning and in the afternoon. Plus, it is possible to stack it for even better potential results!

Sources:

1. Basaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R., Zientek, H., Gordon, G., Kazmi, S., Sheffield-Moore, M., & Bhasin, S. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. The journals of gerontology. Series A, Biological sciences and medical sciences, 68(1), 87–95. https://doi.org/10.1093/gerona/gls078
2. Viking Therapeutics, Inc. (2018, October 1). Viking Therapeutics presents results from Phase 2 study of VK5211 in patients recovering from hip fracture in plenary oral presentation at ASBMR 2018 annual meeting. https://ir.vikingtherapeutics.com/2018-10-01-Viking-Therapeutics-Presents-Results-from-Phase-2-Study-of-VK5211-in-Patients-Recovering-from-Hip-Fracture-in-Plenary-Oral-Presentation-at-ASBMR-2018-Annual-Meeting